Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients
- PMID: 19423571
- PMCID: PMC2689877
- DOI: 10.2215/CJN.00290109
Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients
Abstract
Background and objectives: Dialysis patients have a high burden of co-existing diseases, poor health-related quality of life (HR-QOL), and are prescribed many medications. There are no data on daily pill burden and its relationship to HR-QOL and adherence to therapy.
Design, setting, participants, & measurements: Two hundred and thirty-three prevalent, chronic dialysis patients from three units in different geographic areas in the United States underwent a single, cross-sectional assessment of total daily pill burden and that from phosphate binders. HR-QOL, adherence to phosphate binders, and serum phosphorus levels were the three main outcome measures studied.
Results: The median daily pill burden was 19; in one-quarter of subjects, it exceeded 25 pills/d. Higher pill burden was independently associated with lower physical component summary scale scores on HR-QOL on both univariate and multivariate analyses. Phosphate binders accounted for about one-half of the daily pill burden; 62% of the participants were nonadherent. There was a modest relationship between pill burden from phosphate binders and adherence and serum phosphorus levels; these associations persisted on multivariate analyses. There was no relationship between adherence and serum phosphorus levels.
Conclusions: The daily pill burden in dialysis patients is one of the highest reported to date in any chronic disease state. Higher pill burden is associated with lower HR-QOL. There are many reasons for uncontrolled serum phosphorus levels; increasing the number of prescribed pills does not seem to improve control and may come at the cost of poorer HR-QOL.
Figures





Similar articles
-
Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis.Nephrol Dial Transplant. 2014 Nov;29(11):2092-9. doi: 10.1093/ndt/gft280. Epub 2013 Sep 5. Nephrol Dial Transplant. 2014. PMID: 24009281 Free PMC article.
-
The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.Adv Ther. 2014 Dec;31(12):1272-86. doi: 10.1007/s12325-014-0170-4. Epub 2014 Dec 6. Adv Ther. 2014. PMID: 25479935
-
One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.J Ren Nutr. 2019 Sep;29(5):428-437. doi: 10.1053/j.jrn.2018.11.002. Epub 2019 Jan 21. J Ren Nutr. 2019. PMID: 30679076 Free PMC article.
-
Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.Am J Kidney Dis. 2016 Nov;68(5S1):S24-S32. doi: 10.1053/j.ajkd.2016.05.024. Am J Kidney Dis. 2016. PMID: 27772640 Review.
-
Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.J Nephrol. 2022 Apr;35(3):875-888. doi: 10.1007/s40620-021-01241-5. Epub 2022 Feb 9. J Nephrol. 2022. PMID: 35138627 Free PMC article. Review.
Cited by
-
Survey of dietary and medication practices of owners of cats with chronic kidney disease.J Feline Med Surg. 2015 Dec;17(12):979-83. doi: 10.1177/1098612X14563097. Epub 2014 Dec 22. J Feline Med Surg. 2015. PMID: 25535212 Free PMC article.
-
Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence.BMC Nephrol. 2013 Jul 18;14:153. doi: 10.1186/1471-2369-14-153. BMC Nephrol. 2013. PMID: 23865421 Free PMC article. Review.
-
Medication adherence in Greek hemodialysis patients: the contribution of depression and health cognitions.Int J Behav Med. 2013 Jun;20(2):311-8. doi: 10.1007/s12529-012-9231-8. Int J Behav Med. 2013. PMID: 22407452
-
Comparison of symptom management strategies for pain, erectile dysfunction, and depression in patients receiving chronic hemodialysis: a cluster randomized effectiveness trial.Clin J Am Soc Nephrol. 2013 Jan;8(1):90-9. doi: 10.2215/CJN.04450512. Epub 2012 Sep 27. Clin J Am Soc Nephrol. 2013. PMID: 23024159 Free PMC article. Clinical Trial.
-
Clinical relevance of abstruse transport phenomena in haemodialysis.Clin Kidney J. 2021 Dec 27;14(Suppl 4):i85-i97. doi: 10.1093/ckj/sfab183. eCollection 2021 Dec. Clin Kidney J. 2021. PMID: 34987788 Free PMC article. Review.
References
-
- USRDS 2008 Annual Data Report. US Renal Data System, in 2008
-
- Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB: Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 3: 329–338, 1994 - PubMed
-
- Evans RW, Manninen DL, Garrison LP, Jr., Hart LG, Blagg CR, Gutman RA, Hull AR, Lowrie EG: The quality of life of patients with end-stage renal disease. N Engl J Med 312: 553–559, 1985 - PubMed
-
- Mapes DL, Lopes AA, Satayathum S, McCullough KP, Goodkin DA, Locatelli F, Fukuhara S, Young EW, Kurokawa K, Saito A, Bommer J, Wolfe RA, Held PJ, Port FK: Health-related quality of life as a predictor of mortality and hospitalization: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 64: 339–349, 2003 - PubMed
-
- Lowrie EG, Curtin RB, LePain N, Schatell D: Medical outcomes study short form-36: A consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis 41: 1286–1292, 2003 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical